WLWeijia Liu

Weijia Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Weijia Liu has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Dandan Tang

    School of Chemistry and Life Science, Biology and Materials Engineering, Suzhou University of Science and Technology, 215009 Suzhou, Jiangsu, China

    1 shared publication
  • Haiyu Mou

    Jiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in Oncology, Suzhou Vocational Health College, 215009 Suzhou, Jiangsu, China

    1 shared publication
  • Lili Hou

    Thyroid and Breast Surgery, Wuzhong People’s Hospital of Suzhou City, 215128 Suzhou, Jiangsu, China

    1 shared publication
  • Song-Bai Liu

    Suzhou Key Laboratory of Medical Biotechnology, Suzhou Vocational Health College, Suzhou, China

    1 shared publication
  • Weijie Wang

    College of Life Science, North China University of Science and Technology, 063210 Tangshan, Hebei, China

    1 shared publication
  • Xiaohua Li

    Jiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in Oncology, Suzhou Vocational Health College, 215009 Suzhou, Jiangsu, China

    1 shared publication

Latest Publications

  • Open Access

    EIF4EBP1 in Breast Cancer: Translational Control, Regulatory Networks, and Therapeutic Frontiers

    by Weijia Liu, Lili Hou, Dandan Tang, Haiyu Mou, Weijie Wang, Song-Bai Liu, Xiaohua Li

    Eukaryotic initiation factor 4E-binding protein 1 (EIF4EBP1/4E-BP1) is a pivotal translational regulator with context-dependent roles in breast cancer pathogenesis. Its phosphorylation status, dynamically controlled by mammalian target of rapamycin (mTOR), mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK), and AMP-activated protein kinase (AMPK) signaling, dictates a dualistic function: hypophosphorylated EIF4EBP1 suppresses oncogenesis by sequestering eIF4E and inhibiting cap-dependent translation of pro-tumorigenic mRNAs (e.g., cyclin D1 and c-MYC), while hyperphosphorylation promotes tumor progression and therapeutic resistance. EIF4EBP1 amplification (8p11-p12) is correlated with endocrine resistance and poor prognosis. EIF4EBP1 modulates cell cycle checkpoints, metabolic adaptation under stress, and resistance to cyclin-dependent kinase (CDK) 4 and 6 inhibitors and rapalogs via feedback loops (e.g., SGK3/Akt reactivation). Emerging therapeutic strategies, such as ATP-competitive mTOR inhibitors, bisteric compounds, and agents targeting polyamine metabolism or upstream kinases, exploit the dynamics of EIF4EBP1 phosphorylation. As a biomarker, phosphorylated EIF4EBP1 levels predict tumor aggressiveness and treatment failure, positioning it as a critical node for precision oncology. Future research must address spatial heterogeneity and leverage multi-omics/AI-driven approaches.